Back to search results

ILLUSION Trial: CT-Guided SBRT for Localized Prostate Cancer

This study, called the ILLUSION Trial, is looking at a type of radiation treatment called CT-guided stereotactic body radiation therapy (SBRT) with intrafraction motion monitoring for men with prostate cancer that hasn't spread. SBRT uses special equipment to precisely deliver radiation to tumors, helping to protect healthy tissues. Researchers want to understand the side effects, especially those affecting the urinary and digestive systems, and how this treatment impacts your quality of life. They will also track how well the treatment prevents the cancer from returning over five years. You would receive SBRT over several days, along with CT and MRI scans and blood tests. The study aims to enroll 80 participants.

Study design
This is an interventional study planning to enroll 80 men. It is not specified if it is randomized or blinded.
What's involved
You would undergo CT-guided SBRT over 5 sessions, along with CT and MRI scans and blood sample collection. After treatment, you will have follow-up visits for at least 5 years, then annually.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up for at least 5 years after treatment, then annually thereafter.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06995053

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial

Active, Not Recruiting
NAAges 18+InterventionalTreatment
Jonsson Comprehensive Cancer Center
~91 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyCT-guided Stereotactic Body Radiation TherapyIntrafraction Motion MonitoringMagnetic Resonance ImagingQuestionnaire Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of acute grade ≥ 2 genitourinary (GU) toxicities
Measured over From the start of stereotactic body radiation therapy (SBRT) to 90 days post-SBRT

Conditions

Localized Prostate Adenocarcinoma
Stage I Prostate Cancer AJCC v8
Stage II Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Amar Kishan · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed, clinically localized adenocarcinoma of the prostate
No evidence of metastatic disease in lymph nodes above the bifurcation of the renal arteries, or in bones or visceral organs (nodal disease identified on a prostate-specific membrane antigen \[PSMA\] positron emission tomography \[PET\]/CT scan below the bifurcation of the renal arteries are amenable)
Staging workup as recommended by the National Comprehensive Cancer Network (NCCN) on the basis of risk grouping
Advanced imaging studies (i.e. PSMA PET/CT and fluciclovine PET/CT scan) can supplant a bone scan if performed first
Age ≥ 18
Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study

Exclusion

Patients with neuroendocrine or small cell carcinoma of the prostate
Patients with any evidence of distant metastases except that evidence of lymphadenopathy below the level of the renal arteries can be deemed locoregional per the discretion of the investigator
Prior whole gland cryosurgery, high-intensity focused ultrasound (HIFU) or brachytherapy of the prostate
Prior pelvic radiotherapy
History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia
Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data

What this trial measures

  • Incidence of acute grade ≥ 2 genitourinary (GU) toxicitiesFrom the start of stereotactic body radiation therapy (SBRT) to 90 days post-SBRT

    Will determine physician-scored GU toxicities by the Common Terminology Criteria for Adverse Events, version 5 (CTCAE v5.0) criteria. Rates will be reported descriptively. Point estimates as well as the associated 95% confidence intervals will be reported.